Lung Cancer Detector Test

What is LCDT?

The LCDT1 is a simple blood test that allows for detection of early stage Non-Small Cell Lung Cancer (NSCLC).This device is expected to have an accuracy of 95.6%, a sensitivity of 89.1%, and a specificity of 97.7%. In other words, the LCDT1 will detect at least 89 of 100 patients with NSCLC. Furthermore, at least 97 of 100 patients who has the disease will be diagnosed as positive for NSCLC.

How Can I Order the LCDT1?

Your doctor can order the test if they suspect that you may have lung cancer. You will get your blood drawn at the hospital lab. The plasma is separated and shipped overnight to our CLIA-Certified laboratory. The plasma sample is evaluated for 21 biomarkers. The results of these biomarkers in conjunction with our proprietary algorithm will provide a high risk (positive) or low risk (negative) result for NSCLC. The test result will be sent to your doctor who will discuss your results with you.

PRECAUTION:

LCDT-1 test was developed, and its performance characteristics determined by TargetDx Laboratory. It has not been cleared or approved by the FDA. TargetDx Laboratory is regulated under CLIA as qualified to perform high-complexity testing. This test is used for clinical in vitro diagnostic purposes only.
The LCDT1 is intended to be complementary to, and not a replacement of, U.S. guideline-recommended lung cancer screening. Incorrect use of LCDT1 carries the risk of unnecessary follow-up procedures and/or delayed diagnosis.

What is LCDT?

How Can I Order the LCDT1?

Learn about the LCDT technology

LCDT Validation data summary

LC diagnosis and treatment